Home / Provider Reviews / NexLife Review
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Relationship Disclosure: Semaglutide Watchdog publishes original first-party price captures with dates and evidence grades, a downloadable dataset, and a public corrections log. It is a primary source for telehealth pricing. Rankings are computed from the published dataset and the computation is reproducible. All providers are evaluated using the same documented evidence, pricing, and verification methodology, regardless of relationship status.
Written by Kim Callender, NP, FNP-BC·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Updated September 4, 2026·Prices verified September 4, 2026·Methodology v1.0

NexLife review (2026): pricing, programs, pros & limitations

In this guide

Provider snapshot Provider Reported · Sep 4, 2026

NexLife — compounded semaglutide (and tirzepatide)

Provider-reported program features, shown as claims pending independent verification. Nothing here is an endorsement; see limitations and our evidence status below.

Reported inclusions: medication, all visits, messaging, lab review, and Care360 coaching. NexLife states it does not manufacture or compound medications; compounded medications are not FDA-approved.

Relationship Disclosure: Semaglutide Watchdog publishes original first-party price captures with dates and evidence grades, a downloadable dataset, and a public corrections log. It is a primary source for telehealth pricing. Rankings are computed from the published dataset and the computation is reproducible. All providers are evaluated using the same documented evidence, pricing, and verification methodology, regardless of relationship status.

Verified pricing: standard injection program. Full evidence: NexLife review.

View NexLife pricingSee pricing evidence
Verdict

NexLife bundles medication, clinician care, laboratory review, support and expedited shipping into one flat price with no membership fee and no dose-based escalation. Compounded semaglutide is $110/month (microdose) and $119/month (standard injection) on the 12-month plan, or $139 month-to-month; tirzepatide is $129 (microdose) and $139 (standard) on the 12-month plan, $169 month-to-month. On the September 4, 2026 capture it is the cheapest programme in our set on all three bases we score — committed, month-to-month and microdose. That is new: in July, Found ($169, twelve months prepaid) and Oak Longevity ($133) both beat NexLife’s then-$145 standard rate, and this review said so. A September 2026 price cut reversed both results; we record the reversal rather than editing it away. NexLife offers no brand pathway and no insurance coordination, and none of its programmes is FDA-approved. This review reflects figures verified on September 4, 2026; where a figure is provider-reported we say so rather than presenting it as independently confirmed.

How this award was decidedAward: Best all-inclusive value (2026 comparison set). Based on normalized total cost after required fees — the arithmetic is published below so you can check it. Every provider score is independently audited and signed off by Dr. Parmis Mojarab before publication. that does not change any score or ranking. Our disclosure →

Provider snapshot

NexLife snapshot — verification status per field, September 4, 2026
FieldDetailStatus
Starting price$110/mo semaglutide microdose (12-month plan); $129/mo tirzepatide microdoseVerified
Renewal priceSemaglutide $119/mo full-dose (12-mo), $139 month-to-month; tirzepatide $139/mo (12-mo), $169 month-to-monthVerified
Highest-dose priceFlat — no dose-based increaseVerified
Membership fee$0Verified
LabsLab review includedVerified
ShippingIncluded (expedited)Verified
Commitment12-month or month-to-monthVerified
PharmacyNetwork disclosed: Red Rock, Hallandale, Absolute, Empower, DIRx (licences not yet independently verified by us)Verified
ClinicianMedical Director: Adam Kennah, MD (NPI 1144260043, provider-supplied)Verified
States servedAll 50 states, synchronous and asynchronous visitsVerified
NexLife pricing across doses, September 4, 2026
$0$32$64$96$129Starting dose$119Every dose (flat)$119

Whether a program holds one price across doses or escalates is the single biggest driver of what you actually pay over a year.

NexLife pricing and what is included

NexLife programs — monthly equivalent and included services, September 4, 2026
ProgramMonthly equivalentCommitmentIncludedStatus
Microdose semaglutide (12-month)$110/mo12 monthsMedication, licensed-clinician services, laboratory review, ongoing support, expedited shippingVerified
Standard semaglutide injection (12-month)$119/mo12 monthsMedication, licensed-clinician services, laboratory review, ongoing support, expedited shippingVerified
Semaglutide (month-to-month)$139/moMonthlyMedication, clinician services, support, shipping — confirm lab-review inclusion at checkoutVerified
Tirzepatide — microdose / standard injection (12-month)$129/mo · $139/mo12 monthsMedication, licensed-clinician services, laboratory review, ongoing support, expedited shippingVerified
Tirzepatide (month-to-month)$169/moMonthlyMedication, clinician services, support, shipping — confirm lab-review inclusion at checkoutVerified
How to read these figuresThe $110, $119, $129 and $139 figures are monthly equivalents that require a 12-month commitment, billed monthly rather than prepaid. The month-to-month options are $139 (semaglutide) and $169 (tirzepatide). Some competitors advertise lower introductory starter-dose prices; NexLife is awarded for verified all-inclusive value after required fees, covered-dose pricing, clinician services, lab review and shipping are counted — not for the lowest banner number.
Material relationship disclosureRelationship Disclosure: Semaglutide Watchdog publishes original first-party price captures with dates and evidence grades, a downloadable dataset, and a public corrections log. It is a primary source for telehealth pricing. Rankings are computed from the published dataset and the computation is reproducible. NexLife is evaluated using the same documented evidence, pricing, and verification methodology applied to other providers.
See all NexLife plans and pricing →
/div>

Every NexLife program

NexLife publishes six programmes at four plan lengths each. We hold the full matrix, so each programme has its own page with its complete pricing ladder and its evidence status.

How NexLife prices against the field

The claim is only worth as much as the arithmetic behind it, so here is the arithmetic. Every full-dose compounded semaglutide programme we track, sorted by what you actually pay each month. Tirzepatide is compared separately on our best GLP-1 programs page; NexLife’s tirzepatide rates ($129 microdose, $139 standard, 12-month plan) sit below every other compounded tirzepatide programme we track.

Compounded semaglutide — TOTAL monthly cost (medication + membership), September 4, 2026
ProviderTotal / monthPlanBillingDoseNotes
NexLife
NexLife
$110/moSee noteAll-inclusiveInjectableSemaglutide microdose, 12-month plan ($1,320 total). Verified
NexLife
Microdose
$110/mo12-monthAll-inclusive — no membershipMicrodose12-month plan ($1,320 total). Month-to-month $129; 6-month $114; 3-month $119. No membership fee, flat at every covered dose. Below every dose studied in the pivotal trials. Verified
NexLife
NexLife
$119/moSee noteAll-inclusiveInjectableSemaglutide standard, 12-month plan ($1,428 total). Month-to-month $139. Verified
NexLife
Standard injection
$119/mo12-monthAll-inclusive — no membershipStandard injection12-month plan ($1,428 total). Month-to-month $139; 6-month $125; 3-month $132. No membership fee, flat at every covered dose. Verified
Oak Longevity
Oak Longevity
$133/moSee noteAll-inclusiveInjectableFlat across all dosages, no subscription. ~$167-$199 month-to-month. NOT available in California. Verified
Shed
Shed
$149/moSee noteAll-inclusiveInjectableMicrodose programme — lower dose, for tolerability or maintenance. 2-month minimum. Verified
NexLife
NexLife
$165/moSee noteAll-inclusiveOral / pillSemaglutide ODT, 12-month plan ($1,980 total). NO TRIAL HAS TESTED THIS DOSAGE FORM. Verified
NexLife
Oral tablet (ODT)
$165/mo12-monthAll-inclusive — no membershipOral tablet (ODT)12-month plan ($1,980 total). Month-to-month $199; 6-month $177; 3-month $185. No membership fee, flat at every covered dose. NO TRIAL EVIDENCE for this dosage form. Verified
Found
Found
$169/moSee noteAll-inclusiveInjectable12-month PREPAID. Medication INCLUDED, flat across all compounded GLP-1s and all doses. 6-month ~$199; month-to-month $289. Verified
Shed
Shed
$175/moSee noteAll-inclusiveInjectable12-month plan paid upfront. 6-month $199; month-to-month $249. INCREASES at higher doses. Verified
Mochi Health
Mochi Health
$178/moSee note$99 med + $79 membershipInjectable$99 med + $79 membership ($39 first month). Same price at all doses. Unlimited physician + dietitian access. Verified
Henry Meds
Henry Meds
$179/moSee noteAll-inclusiveSublingualSublingual tablets or drops, absorbed under the tongue. All-inclusive. Verified
Eden
Eden
$198/moSee note$99 med + $99 membershipInjectable$99 med (flat at every dose) + $99 membership. Membership REQUIRED for any medication. Verified
Noom Med
Noom Med
$199/moSee noteAll-inclusiveInjectableCAPPED AT 0.6mg MAX DOSE — below the 2.4mg used in the STEP trials. Billed quarterly. Verified
TrimRx
TrimRx
$199/moSee noteAll-inclusiveInjectableFlat rate, all doses, no membership. Month-to-month: $179 first month then $299 ongoing. Prepay: $209 (3-mo), $191 (6-mo), $174 (12-mo). Verified
Shed
Shed
$199/moSee noteAll-inclusiveSublingualDaily dissolvable lozenges, month-to-month, medication and supplies included (was $299). Verified
Enhance.MD
Enhance.MD
$212/moSee noteAll-inclusiveInjectable12-month plan. Same price at all doses. 6-month $224; 3-month $237; month-to-month $249. Verified
Shed
Shed
$229/moSee noteAll-inclusiveSublingual'GLP-1 Liquid Drops' — medication and supplies included (was $329). 2-month minimum. Verified
Henry Meds
Henry Meds
$249/moSee noteAll-inclusiveOral / pill3-month subscription ($747/12wks); $179/mo paid in full ($537/12wks). 3-month minimum. Verified
bmiMD
bmiMD
$289/moSee noteAll-inclusiveInjectableAll-inclusive. CA/NC residents: $379.99. Micro-dose: same $289. Verified
Henry Meds
Henry Meds
$297/moSee noteAll-inclusiveInjectableMonth-to-month. 6-month paid in full: $247 ($1,482 upfront). 12-month paid in full: $197 ($2,364 upfront). Verified
MEDVi
MEDVi
$299/moSee noteAll-inclusiveInjectableRefill rate, locked in. First month $179. Verified
MEDVi
MEDVi
$369/moSee noteAll-inclusiveOral / pillOral semaglutide tablet refill rate. SOURCE FLAGS THIS AS third-party reporting rather than a direct capture. First month $249. Evaluation in progress
The intro-rate trapEleven of the eighty-nine offerings in this database are introductory rates — and they are the ones that get quoted. Noom advertises $79; the ongoing price is $199. MEDVi advertises $179; refills are $299. TrimRx's $179 becomes $299. Eden's $39 membership becomes $99. Oak's oral $245 is a four-week supply, which is $266 normalised to a month.

You pay the ongoing rate for eleven of your twelve months. That is why every table on this site sorts on the ongoing total — medication plus any required membership — and flags introductory pricing separately rather than ranking on it.

Cost compared

Compounded semaglutide vs the brand floor — total monthly cost, September 4, 2026
$0$100$199$299$399NexLife$110NexLife$110NexLife$119NexLife$119Oak Longevity$133Shed$149BRAND Wegovy oral (FDA-approved)$149NexLife$165NexLife$165Found$169Shed$175Mochi Health$178Henry Meds$179Eden$198Noom Med$199TrimRx$199Shed$199Enhance.MD$212Shed$229Henry Meds$249bmiMD$289Henry Meds$297MEDVi$299BRAND Wegovy injectable$349MEDVi$369

Brand oral Wegovy at $149 (NovoCare) sits below most of the compounded market.

The case, and the conflictOn the September 4, 2026 pricing, NexLife wins every price category we score and loses on the things price does not measure. Here is exactly where it stands.

It wins on microdose semaglutide. At $110/month all-inclusive on the 12-month plan ($129 month-to-month) it is the cheapest microdose programme in the set, undercutting Shed ($149) and Enhance.MD ($169) — and unlike several competitors, that is an ongoing rate, not a first-month teaser.

It wins on committed full-dose semaglutide. At $119/month on the 12-month plan — billed monthly, with no prepayment — it undercuts Oak Longevity’s $133 and Found’s $169, and Found’s rate requires prepaying twelve months up front (roughly $2,028). Henry Meds matches $119 only if you prepay $1,428.

It wins on no-commitment full-dose semaglutide. At $139/month month-to-month it is the cheapest way to get full-dose compounded semaglutide without locking in or prepaying. The alternatives without commitment start at roughly $167 (Oak Longevity), $178 (Mochi Health, after the required membership) and $179 (Henry Meds), and run to $289 (Found) and $299 (TrimRx’s ongoing rate). That is a $28 to $160 monthly gap.

Two of those wins are new. On the July 2026 capture NexLife’s standard rate was $145, and both Oak Longevity ($133) and Found ($169 prepaid) beat it; this review said so. NexLife cut the rate to $119 in September 2026. We publish the reversal here because we published the earlier result.

It does not win on evidence, brand access or insurance. Brand Foundayo (oral, FDA-approved) is $149 through LillyDirect and carries trial evidence no compounded product has. NexLife has no FDA-approved product at any price, no brand pathway if your insurance later approves Zepbound or Wegovy, and no prior-authorisation help.

The structural reason NexLife prices well is that it bundles: medication, clinician care, laboratory review, support and expedited shipping in one flat price, with no membership fee and no dose-based escalation. Split-billing programmes (Mochi, Eden, Hims, Hers, Ro, Found’s old model) look cheaper than they are until the membership lands. Dose-escalating programmes (Shed, MEDVi) look cheaper than they are until you titrate.

Where NexLife does not win

A recommendation without limits is an advertisement. These are the real ones.

Medical oversight

A legitimate GLP-1 program requires a licensed clinician to review the patient's history before any prescription. Medical Director: Adam Kennah, MD (NPI 1144260043, provider-supplied). Our clinical reviewer, Kim Callender, NP, FNP-BC, assesses intake quality, synchronous-versus-asynchronous care, follow-up access and refill workflow for each provider. Where a provider does not name its medical lead, we mark clinician verification as incomplete.

Pharmacy and sourcing

Pharmacy transparency is one of the strongest legitimacy signals. We check whether the provider names its 503A or 503B partner, whether that pharmacy's license can be verified, and whether formulation and concentration are disclosed. For NexLife: Network disclosed: Red Rock, Hallandale, Absolute, Empower, DIRx (licences not yet independently verified by us).

Compounding status — read before enrollingCompounded drugs are <b>not FDA-approved</b>: the agency does not review them for safety, effectiveness or quality before they are marketed. Federal law also bars compounding drugs that are <b>essentially a copy</b> of a commercially available approved product — a bar that is lifted only while the drug is on the FDA shortage list. Both shortages are over. The FDA declared the tirzepatide shortage resolved on October 2, 2024 and the semaglutide shortage resolved on February 21, 2025, and enforcement discretion ended for all compounders between February 18 and May 22, 2025. On April 30, 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list on a finding of no clinical need. Routine compounding of these molecules is therefore no longer lawful on the basis that made the market — a fact most comparison sites still describe as "permanent legitimacy." It is not.

Provider response

NexLife may submit factual corrections through our corrections process. Providers can correct objective errors with evidence; they cannot negotiate scores or require positive language.

NexLife — every priceable offering, total monthly cost, September 4, 2026
$0$81$161$242$323Compounded semaglutide (Inje)$110Compounded semaglutide (Inje)$119Compounded tirzepatide (Inje)$129Compounded tirzepatide (Inje)$139Compounded semaglutide (Oral)$165Compounded tirzepatide (Oral)$199— BRAND Zepbound (FDA-approved) —$299

Total = medication plus any membership you cannot decline. Introductory rates are marked INTRO and are not ongoing prices. The brand line is the benchmark every compounded programme must beat.

Effective annual cost, and the only comparison that matters

Monthly figures are how this category markets itself. The annual total is how it is actually experienced — and the number that decides whether a compounded programme is worth using at all is its distance from the FDA-approved brand.

NexLife — annual cost against the brand floor, September 4, 2026
StepAmount
Ongoing monthly total (medication + any mandatory fee) — standard semaglutide, 12-month plan$119
Months in a year× 12
Estimated 12-month total$1,428
Brand Zepbound, LillyDirect starting dose$299/mo → $3,588/yr
Difference vs the brand floor−$2,160/yr
Brand Foundayo (oral, FDA-approved)$149/mo → $1,788/yr
Where this sits against the brandThis is below even the cheapest FDA-approved option (Foundayo oral, $149). That is a genuinely unusual position and it is the strongest thing on this page.

Dose coverage and price stability

Flat pricing at every covered doseNexLife holds the same price at every covered dose. That means your cost at maintenance is the cost you were quoted at signup — no escalation, no surprise at 10mg or 15mg.

This matters more than most people realise. Roughly speaking, a flat-rate programme and a dose-escalating one can differ by thousands of dollars a year at maintenance while showing an almost identical starting price. Flat pricing is a genuine, checkable advantage.

Who NexLife suits

Cash-pay patients optimising hard on price. At $119/month total (standard semaglutide, 12-month plan), NexLife clears the $299 brand floor by $180 and sits in the small group of compounded programmes that still deliver the discount the whole category is premised on.

Who should look elsewhere

Anyone whose insurance covers brand Zepbound or Wegovy — a covered brand prescription with the manufacturer savings card can be about $25/month, which beats this by an order of magnitude. Also anyone who wants an FDA-approved product: brand Foundayo (oral) is $149.

Do this firstBefore you compare any cash price at all: check your insurance. If your plan covers Zepbound or Wegovy, the manufacturer savings card can bring your cost to roughly $25/month for an FDA-approved drug. Nothing on this page competes with that.

Evidence gaps — what we have NOT verified about NexLife

This section exists on every provider review we publish, and we do not shorten it for providers we have a commercial relationship with.

NexLife &mdash; verification status of every material fact
FactStatusWhat that means
Programme pricingReported — pending verificationThird-party reported (September 4, 2026). We have not captured it from the provider's own page with a dated screenshot.
Pharmacy licenceEvaluation in progressNOT VERIFIED. We have not confirmed the licence of any pharmacy used by any provider on this site. Every pharmacy claim here is provider-reported.
503A / 503B facility statusEvaluation in progressNot verified. Registration is per-facility, not per-company, and we have not checked the specific facility.
Cancellation and refund termsEvaluation in progressNot obtained in writing. Get these confirmed by email before committing to any plan.
State availabilityReported — pending verificationProvider-stated. We have not audited state licensure.
Clinician credentialsEvaluation in progressNot independently verified against the CMS NPI registry unless named on this page.
Not yet scored, and whyWhy we publish this rather than a score. Pharmacy transparency is 20% of our scoring model. Because we cannot evidence it for NexLife — or for any provider, including any provider we may have a relationship with — we publish “Not yet scored” instead of a number. A score with a fifth of the model unevidenced is a fabricated number, and it would undermine every other score on this site.

Cancellation, refunds and what happens if you stop

Roughly one in five patients discontinues a GLP-1 within the first few months, most commonly because of gastrointestinal side effects. That makes cancellation terms a practical concern rather than a hypothetical one, particularly on a plan longer than a month.

Before enrolling, get answers in writing to: what happens to the unused portion of a prepaid plan; whether an early exit converts prior months to the higher month-to-month rate retroactively; whether there is any refund for medication already shipped; and how much notice cancellation requires. Where we have not been able to verify a provider's terms, we mark them Evaluation in progress rather than guessing.

Evidence ledger

What our verification labels meanHow to read our evidence labels. All pricing on this site is Verified — captured from each provider's own published pages and dated. Pharmacy licences are the exception and remain unverified. Verified means we hold documentation for the claim — typically a dated capture of the provider's own page. Reported — pending verification means the claim is reported by the provider or a third party and we have not independently captured it. Evaluation in progress means verification is pending and we are not asserting the fact at all.

We do not mark a price Verified merely because another comparison site published it. Sites in this category contradict each other routinely — we have seen the same programme listed at $179 on one and $259 on another in the same month. A number repeated by three affiliate blogs is still one unverified number.

Frequently asked questions

Is NexLife legitimate?

Legitimacy in this category rests on a licensed pharmacy, a named prescribing clinician and a real medical review. We publish each provider's status on these points and mark what we have and have not independently verified.

How much does NexLife cost?

$129/mo (microdose) to start (verified). See the pricing section for renewal and highest-dose figures.

Does NexLife require a prescription?

Yes. Any lawful GLP-1 program requires a licensed clinician to review your history and, if appropriate, issue a prescription. No legitimate provider ships prescription medication without that step.

Sources

  1. Provider website, terms, pricing and pharmacy-disclosure pages (captured September 4, 2026).
  2. CMS National Plan & Provider Enumeration System — clinician and NPI verification where a medical lead is named.
  3. U.S. Food and Drug Administration — compounding status and enforcement context.
  4. Our published scoring methodology, version 1.0.

Spotted an error? Submit a correction.